Veinlite LEDX®

Unlike IV access which targets a single point, sclerotherapy requires visualizing entire venous networks to identify all feeder veins, assess vein diameter along its course, and plan optimal injection sites. LEDX's wide illumination field allows you to see the complete vascular pattern before beginning treatment.

Studies show inadvertent arterial injection is a catastrophic complication of sclerotherapy. LEDX helps differentiate between superficial veins (treatment targets) and nearby arteries, reducing this risk. It also helps ensure accurate intra-vascular injection, avoiding extravasation that causes tissue necrosis.

Yes—this is critical. Spider veins often have underlying reticular feeder veins that must be treated to prevent recurrence. These feeder veins may not be visible to the naked eye. LEDX reveals these deeper feeding vessels, allowing more complete treatment and better long-term outcomes.

For superficial vessels, LEDX offers advantages: no gel required, real-time visualization during injection without holding a probe, and ability to see wide vascular patterns at once. While ultrasound remains valuable for deeper varicose veins, LEDX is ideal for telangiectasias, reticular veins, and spider vein complexes.

By visualizing the entire treatment area simultaneously, you can plan injection sites more strategically, identify all vessels requiring treatment in one assessment, and reduce the chance of missing contributing vessels. This means fewer treatment sessions and better outcomes per visit.

Hyperpigmentation occurs in 0.3-30% of cases and is more common when excessive sclerosant is used or when the same vessel is treated multiple times. LEDX helps you accurately target vessels, judge appropriate sclerosant volume, and avoid re-treating already-closed vessels, potentially reducing pigmentation risk.

Yes. During foam sclerotherapy, you can visualize vein clearance as the sclerosant displaces blood. With LEDX illumination, you can confirm the foam is staying within the target vessel and see when the vein has adequately constricted, helping you determine if you've delivered sufficient sclerosant.

Matting (development of new fine vessels) occurs in some patients after sclerotherapy. Identifying early matting and underlying reticular veins that may contribute requires excellent superficial vein visualization. LEDX helps detect these fine vessels early and plan appropriate retreatment.

Absolutely. Clinical success in vein treatment depends on accurate vessel identification regardless of skin tone or body habitus. LEDX's illumination penetrates through melanin and adipose tissue, ensuring equitable treatment outcomes across diverse patient populations.

Studies show patients expect 50-80% clearance of treated veins per session. Complete visualization with LEDX helps you treat all contributing vessels comprehensively, deliver sclerosant accurately, and avoid complications like hyperpigmentation—all factors that improve cosmetic outcomes and patient satisfaction.